Objective:To observe the clinical efficacy and safety of oral administration of the traditional Chinese herb rhubarb to treat acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Method:This was a multi...Objective:To observe the clinical efficacy and safety of oral administration of the traditional Chinese herb rhubarb to treat acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Method:This was a multicenter randomized double-blinded placebo controlled study that took place in 7 provinces of China that enrolled 244 patients(aged 18e80 years)who had acute exacerbation of COPD with the traditional Chinese syndrome pattern of phlegm-heat obstructing lung.Participants were divided into experimental and control groups.The experimental group received 4.5 g of rhubarb granules twice daily and the control group received placebo granules.Both groups also received conventional Western therapy consisting of oxygen therapy,an antibiotic,expectorant,and a bronchodilator.Treatment lasted 10 days.Symptom scores for cough,sputum volume and color,wheezing and chest tightness before treatment and on days 3,5,7,and 10 during the treatment were recorded.Lung function,arterial blood gas and levels of serum inflammatory factors,interleukin-4(IL-4),interleukin-8(IL-8),and interleukin-10(IL-10)and tumor necrosis factor-alpha(TNF-a),before and after treatment were measured.Results:The sample size of the full analysis set(FAS)was 244 participants,and the sample size of per protocol set(PPS)was 235.Following 10 days’treatment,symptom scores of the experimental group were markedly lower than those of the placebo group(FAS:mean difference1.67,95%CI:e2.66 to0.69,P Z 0.001;PPS:mean difference1.55,95%CI:2.56 to0.54,P Z 0.003).Lung function in the experimental group was significantly higher than in the placebo group(FEV1,FAS:mean difference 0.12,95%CI:0.06 to 0.18;P<0.001;PPS:mean difference 0.12,95%CI 0.05 to 0.18;P<0.001.FVC:FAS:mean difference 0.16,95%CI:0.06 to 0.26;P Z 0.002;PPS:mean difference 0.16,95%CI 0.05 to 0.26;P Z 0.003.FEV1%,FAS:mean difference 5.95,95%CI:3.36 to 8.53;P<0.001;PPS:mean difference 5.92,95%CI 3.28 to 8.56;P<0.001.).PaO2,PaCO2,as well as serum inflammatory factors were also improved when compared to the placebo group.There were no significant differences in the incidence rate of adverse reaction between the two groups.Conclusions:Compared with placebo,rhubarb granules significantly reduced symptom scores,improved blood oxygen level,controlled systemic inflammatory response,without significant adverse effects.Thus,rhubarb may be a beneficial adjuvant method for treating the phlegm-heat obstructing the lung syndrome pattern of AECOPD.展开更多
Obstructive sleep apnea syndrome(OSAS) is a widespread disorder, characterized by recurrent upper airway obstruction during sleep, mostly as a result of complete or partial pharyngeal obstruction. Due to the occurrenc...Obstructive sleep apnea syndrome(OSAS) is a widespread disorder, characterized by recurrent upper airway obstruction during sleep, mostly as a result of complete or partial pharyngeal obstruction. Due to the occurrence of frequent and regular hypoxic events, patients with OSAS are at increased risk of cardiovascular disease, stroke, metabolic disorders, occupational errors, motor vehicle accidents and even death. Thus, OSAS has severe consequences and represents a significant economic burden. However, some of the consequences, as well as their costs can be reduced with appropriate detection and treatment. In this context, the recent advances that were made in stem cell biology knowledge and stem cell- based technologies hold a great promise for various medical conditions, including respiratory diseases. However, the investigation of the role of stem cells in OSAS is still recent and rather limited, requiring further studies, both in animal models and humans. The goal of this review is to summarize the current state of knowledge regarding both lung resident as well as circulating stem/progenitor cells and discuss existing controversies in the field in order to identify future research directions for clinical applications in OSAS. Also, the paper highlights the requisite for inter-institutional, multi-disciplinary research collaborations in order to achieve breakthrough results in the field.展开更多
BACKGROUND Acute exacerbation of chronic obstructive pulmonary disease(AECOPD)is a serious complication of chronic obstructive pulmonary disease,often characterized by increased morbidity and mortality.In traditional ...BACKGROUND Acute exacerbation of chronic obstructive pulmonary disease(AECOPD)is a serious complication of chronic obstructive pulmonary disease,often characterized by increased morbidity and mortality.In traditional Chinese medicine,AECOPD is linked to phlegm-heat and blood-stasis,presenting symptoms like thick sputum,fever,and chest pain.It has been shown that acetylcysteine inhalation in conjunction with conventional therapy significantly reduced inflammatory markers and improved lung function parameters in patients with AECOPD,suggesting that acetylcysteine may be an important adjunctive therapy for patients with phlegm-heat-blood stasis type AECOPD.AIM To investigate the effect of acetylcysteine on microinflammation and lung ventilation in patients with phlegm-heat and blood-stasis-type AECOPD.METHODS One hundred patients with phlegm-heat and blood-stasis-type AECOPD were randomly assigned to two groups.The treatment group received acetylcysteine inhalation(10%solution,5 mL,twice daily)along with conventional therapy,whereas the control group received only conventional therapy.The treatment duration was 14 d.Inflammatory markers(C-reactive protein,interleukin-6,and tumor necrosis factor-alpha)in the serum and sputum as well as lung function parameters(forced expiratory volume in one second,forced vital capacity,and peak expiratory flow)were assessed pre-and post-treatment.Acetylcysteine inhalation led to significant reductions in inflammatory markers and improvements in lung function parameters compared to those in the control group(P<0.05).This suggests that acetylcysteine could serve as an effective adjunct therapy for patients with phlegm-heat and blood-stasis-type AECOPD.RESULTS Acetylcysteine inhalation significantly reduced inflammatory markers in the serum and sputum and improved lung ventilation function parameters in patients with phlegm-heat and blood-stasis type AECOPD compared with the control group.These differences were statistically significant(P<0.05).The study concluded that acetylcysteine inhalation had a positive effect on microinflammation and lung ventilation function in patients with this type of AECOPD,suggesting its potential as an adjuvant therapy for such cases.CONCLUSION Acetylcysteine inhalation demonstrated significant improvements in reducing inflammatory markers in the serum and sputum,as well as enhancing lung ventilation function parameters in patients with phlegm-heat and bloodstasis type AECOPD.These findings suggest that acetylcysteine could serve as a valuable adjuvant therapy for individuals with this specific type of AECOPD,offering benefits for managing microinflammation and optimizing lung function.展开更多
目的 观察清金贝蒌汤加减联合布地奈德治疗痰热郁肺型慢性阻塞性肺疾病(Chronic obstructive pulmonary disease,COPD)的临床疗效。方法 选取2021年2月—2022年6月期间重庆市大足区人民医院收治的86例痰热郁肺型COPD患者作为试验对象开...目的 观察清金贝蒌汤加减联合布地奈德治疗痰热郁肺型慢性阻塞性肺疾病(Chronic obstructive pulmonary disease,COPD)的临床疗效。方法 选取2021年2月—2022年6月期间重庆市大足区人民医院收治的86例痰热郁肺型COPD患者作为试验对象开展研究,按照随机数字表法分为对照组和试验组,每组各43例。在常规治疗基础上,对照组给予吸入用布地奈德混悬液雾化吸入,试验组给予布地奈德+清金贝蒌汤治疗,两组患者均治疗10 d。观察比较两组患者临床疗效、不良反应情况,治疗前后中医症状积分、肺功能[第1秒用力呼气量(First second forced expiratory volume,FEV1)、第1秒用力呼气量占预计百分比(Expected percentage of forced expiratory volume in the first second,FEV1%)、用力肺活量(Forced vital capacity,FVC)及第1秒用力呼气量占用力肺活量百分比(The percentage of forced expiratory volume to forced vital capacity in the first second,FEV1/FVC)]、血气分析指标[血氧分压(Partial pressure of oxygen,PaO_(2))、二氧化碳分压(Partial pressure of carbon dioxide,PaCO_(2))、动脉氧合指数(Ratio of partial pressure of O2 in arterial blood to fraction of inspired oxygen,PaO_(2)/FiO_(2))]水平变化。结果 治疗后试验组临床疗效总有效率95.35%(41/43)与对照组90.70%(39/43)比较,差异无统计学意义(P>0.05);试验组临床控制率62.79%(27/43)明显高于对照组44.19%(19/43),差异有统计学意义(P<0.05)。治疗后两组患者中医症状喘急、咳嗽、痰量、痰色及痰质积分均较治疗前降低,差异有统计学意义(P<0.05);且试验组中医症状喘急、咳嗽、痰量、痰色及痰质积分均明显低于对照组,差异有统计学意义(P<0.05)。治疗后两组患者肺功能FVE1、FEV1%、FVC、FEV1/FVC指标均较治疗前升高,差异有统计学意义(P<0.05);且试验组肺功能FVE1、FEV1%、FVC、FEV1/FVC指标均明显高于对照组,差异有统计学意义(P<0.05)。治疗后两组患者PaO_(2)、PaO_(2)/FiO_(2)水平均较治疗前升高,PaCO_(2)均较治疗前降低,差异有统计学意义(P<0.05);且试验组PaO_(2)、PaO_(2)/FiO_(2)水平均明显高于对照组,PaCO_(2)水平明显低于对照组,差异有统计学意义(P<0.05)。治疗期间,试验组不良反应发生率9.30%(4/43)与对照组6.98%(3/43)比较,差异无统计学意义(P>0.05)。结论 清金贝蒌汤加减辅助布地奈德治疗痰热郁肺型COPD安全、有效,有利于提高患者肺功能、改善血气状态。展开更多
基金This study was funded by the China National Key Basic Research Project through The Ministry of Science and Technology(No.2009CB522704).
文摘Objective:To observe the clinical efficacy and safety of oral administration of the traditional Chinese herb rhubarb to treat acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Method:This was a multicenter randomized double-blinded placebo controlled study that took place in 7 provinces of China that enrolled 244 patients(aged 18e80 years)who had acute exacerbation of COPD with the traditional Chinese syndrome pattern of phlegm-heat obstructing lung.Participants were divided into experimental and control groups.The experimental group received 4.5 g of rhubarb granules twice daily and the control group received placebo granules.Both groups also received conventional Western therapy consisting of oxygen therapy,an antibiotic,expectorant,and a bronchodilator.Treatment lasted 10 days.Symptom scores for cough,sputum volume and color,wheezing and chest tightness before treatment and on days 3,5,7,and 10 during the treatment were recorded.Lung function,arterial blood gas and levels of serum inflammatory factors,interleukin-4(IL-4),interleukin-8(IL-8),and interleukin-10(IL-10)and tumor necrosis factor-alpha(TNF-a),before and after treatment were measured.Results:The sample size of the full analysis set(FAS)was 244 participants,and the sample size of per protocol set(PPS)was 235.Following 10 days’treatment,symptom scores of the experimental group were markedly lower than those of the placebo group(FAS:mean difference1.67,95%CI:e2.66 to0.69,P Z 0.001;PPS:mean difference1.55,95%CI:2.56 to0.54,P Z 0.003).Lung function in the experimental group was significantly higher than in the placebo group(FEV1,FAS:mean difference 0.12,95%CI:0.06 to 0.18;P<0.001;PPS:mean difference 0.12,95%CI 0.05 to 0.18;P<0.001.FVC:FAS:mean difference 0.16,95%CI:0.06 to 0.26;P Z 0.002;PPS:mean difference 0.16,95%CI 0.05 to 0.26;P Z 0.003.FEV1%,FAS:mean difference 5.95,95%CI:3.36 to 8.53;P<0.001;PPS:mean difference 5.92,95%CI 3.28 to 8.56;P<0.001.).PaO2,PaCO2,as well as serum inflammatory factors were also improved when compared to the placebo group.There were no significant differences in the incidence rate of adverse reaction between the two groups.Conclusions:Compared with placebo,rhubarb granules significantly reduced symptom scores,improved blood oxygen level,controlled systemic inflammatory response,without significant adverse effects.Thus,rhubarb may be a beneficial adjuvant method for treating the phlegm-heat obstructing the lung syndrome pattern of AECOPD.
文摘Obstructive sleep apnea syndrome(OSAS) is a widespread disorder, characterized by recurrent upper airway obstruction during sleep, mostly as a result of complete or partial pharyngeal obstruction. Due to the occurrence of frequent and regular hypoxic events, patients with OSAS are at increased risk of cardiovascular disease, stroke, metabolic disorders, occupational errors, motor vehicle accidents and even death. Thus, OSAS has severe consequences and represents a significant economic burden. However, some of the consequences, as well as their costs can be reduced with appropriate detection and treatment. In this context, the recent advances that were made in stem cell biology knowledge and stem cell- based technologies hold a great promise for various medical conditions, including respiratory diseases. However, the investigation of the role of stem cells in OSAS is still recent and rather limited, requiring further studies, both in animal models and humans. The goal of this review is to summarize the current state of knowledge regarding both lung resident as well as circulating stem/progenitor cells and discuss existing controversies in the field in order to identify future research directions for clinical applications in OSAS. Also, the paper highlights the requisite for inter-institutional, multi-disciplinary research collaborations in order to achieve breakthrough results in the field.
文摘BACKGROUND Acute exacerbation of chronic obstructive pulmonary disease(AECOPD)is a serious complication of chronic obstructive pulmonary disease,often characterized by increased morbidity and mortality.In traditional Chinese medicine,AECOPD is linked to phlegm-heat and blood-stasis,presenting symptoms like thick sputum,fever,and chest pain.It has been shown that acetylcysteine inhalation in conjunction with conventional therapy significantly reduced inflammatory markers and improved lung function parameters in patients with AECOPD,suggesting that acetylcysteine may be an important adjunctive therapy for patients with phlegm-heat-blood stasis type AECOPD.AIM To investigate the effect of acetylcysteine on microinflammation and lung ventilation in patients with phlegm-heat and blood-stasis-type AECOPD.METHODS One hundred patients with phlegm-heat and blood-stasis-type AECOPD were randomly assigned to two groups.The treatment group received acetylcysteine inhalation(10%solution,5 mL,twice daily)along with conventional therapy,whereas the control group received only conventional therapy.The treatment duration was 14 d.Inflammatory markers(C-reactive protein,interleukin-6,and tumor necrosis factor-alpha)in the serum and sputum as well as lung function parameters(forced expiratory volume in one second,forced vital capacity,and peak expiratory flow)were assessed pre-and post-treatment.Acetylcysteine inhalation led to significant reductions in inflammatory markers and improvements in lung function parameters compared to those in the control group(P<0.05).This suggests that acetylcysteine could serve as an effective adjunct therapy for patients with phlegm-heat and blood-stasis-type AECOPD.RESULTS Acetylcysteine inhalation significantly reduced inflammatory markers in the serum and sputum and improved lung ventilation function parameters in patients with phlegm-heat and blood-stasis type AECOPD compared with the control group.These differences were statistically significant(P<0.05).The study concluded that acetylcysteine inhalation had a positive effect on microinflammation and lung ventilation function in patients with this type of AECOPD,suggesting its potential as an adjuvant therapy for such cases.CONCLUSION Acetylcysteine inhalation demonstrated significant improvements in reducing inflammatory markers in the serum and sputum,as well as enhancing lung ventilation function parameters in patients with phlegm-heat and bloodstasis type AECOPD.These findings suggest that acetylcysteine could serve as a valuable adjuvant therapy for individuals with this specific type of AECOPD,offering benefits for managing microinflammation and optimizing lung function.
文摘目的 观察清金贝蒌汤加减联合布地奈德治疗痰热郁肺型慢性阻塞性肺疾病(Chronic obstructive pulmonary disease,COPD)的临床疗效。方法 选取2021年2月—2022年6月期间重庆市大足区人民医院收治的86例痰热郁肺型COPD患者作为试验对象开展研究,按照随机数字表法分为对照组和试验组,每组各43例。在常规治疗基础上,对照组给予吸入用布地奈德混悬液雾化吸入,试验组给予布地奈德+清金贝蒌汤治疗,两组患者均治疗10 d。观察比较两组患者临床疗效、不良反应情况,治疗前后中医症状积分、肺功能[第1秒用力呼气量(First second forced expiratory volume,FEV1)、第1秒用力呼气量占预计百分比(Expected percentage of forced expiratory volume in the first second,FEV1%)、用力肺活量(Forced vital capacity,FVC)及第1秒用力呼气量占用力肺活量百分比(The percentage of forced expiratory volume to forced vital capacity in the first second,FEV1/FVC)]、血气分析指标[血氧分压(Partial pressure of oxygen,PaO_(2))、二氧化碳分压(Partial pressure of carbon dioxide,PaCO_(2))、动脉氧合指数(Ratio of partial pressure of O2 in arterial blood to fraction of inspired oxygen,PaO_(2)/FiO_(2))]水平变化。结果 治疗后试验组临床疗效总有效率95.35%(41/43)与对照组90.70%(39/43)比较,差异无统计学意义(P>0.05);试验组临床控制率62.79%(27/43)明显高于对照组44.19%(19/43),差异有统计学意义(P<0.05)。治疗后两组患者中医症状喘急、咳嗽、痰量、痰色及痰质积分均较治疗前降低,差异有统计学意义(P<0.05);且试验组中医症状喘急、咳嗽、痰量、痰色及痰质积分均明显低于对照组,差异有统计学意义(P<0.05)。治疗后两组患者肺功能FVE1、FEV1%、FVC、FEV1/FVC指标均较治疗前升高,差异有统计学意义(P<0.05);且试验组肺功能FVE1、FEV1%、FVC、FEV1/FVC指标均明显高于对照组,差异有统计学意义(P<0.05)。治疗后两组患者PaO_(2)、PaO_(2)/FiO_(2)水平均较治疗前升高,PaCO_(2)均较治疗前降低,差异有统计学意义(P<0.05);且试验组PaO_(2)、PaO_(2)/FiO_(2)水平均明显高于对照组,PaCO_(2)水平明显低于对照组,差异有统计学意义(P<0.05)。治疗期间,试验组不良反应发生率9.30%(4/43)与对照组6.98%(3/43)比较,差异无统计学意义(P>0.05)。结论 清金贝蒌汤加减辅助布地奈德治疗痰热郁肺型COPD安全、有效,有利于提高患者肺功能、改善血气状态。
文摘目的探讨咳喘定穴位贴敷联合小柴胡汤合半夏厚朴汤治疗痰浊阻肺证慢性阻塞性肺疾病(Chronic obstructive pulmonary disease,COPD)患者的临床疗效。方法选取2020年9月—2022年10月期间海南医学院第二附属医院收治的痰浊阻肺证COPD患者144例,按随机数字表法分为西药组、中药组、中药联合贴敷组,每组各48例。西药组采取常规西医治疗,中药组在西药基础上采取小柴胡汤合半夏厚朴汤治疗,中药联合贴敷组在常规西医基础上采取咳喘定穴位贴敷及小柴胡汤合半夏厚朴汤。治疗4周后,观察比较3组患者临床疗效、不良反应发生率、疾病复发率及治疗前后中医证候积分、肺功能[第1秒用力呼气容积(Forced expiratory volume for 1 second,FEV_(1))、用力肺活量(Forced vital capacity,FVC)、FEV_(1)/FVC]、康复效果[慢性阻塞性肺疾病评估测试量表(Chronic obstructive Pulmonary Disease Assessment Test Scale,CAT)、呼吸困难程度评分(modified Medical Research Council,mMRC)、6 min步行距离试验(6 min walking distance test,6MWT)]。结果治疗后中药联合贴敷组总有效率93.75%(45/48)高于西药组77.08%(37/48)、中药组79.17%(38/48),差异有统计学意义(P<0.05)。治疗后3组患者中医证候痰多、喘息、咳嗽、倦怠乏力、腹胀纳呆、下肢水肿积分均较治疗前降低,差异有统计学意义(P<0.05),且中药联合贴敷组中医证候痰多、喘息、咳嗽、倦怠乏力、腹胀纳呆、下肢水肿积分均明显低于西药组、中药组,差异有统计学意义(P<0.05)。治疗后3组患者肺功能FEV_(1)、FVC、FEV_(1)/FVC指标均较治疗前升高,差异有统计学意义(P<0.05);且中药联合贴敷组肺功能FEV_(1)、FVC、FEV_(1)/FVC指标明显高于西药组、中药组,差异有统计学意义(P<0.05)。治疗后3组患者康复效果CAT、mMRC评分较治疗前降低,6MWT较治疗前延长,差异有统计学意义(P<0.05);且中药联合贴敷组康复效果CAT、mMRC评分均明显低于西药组、中药组,6MWT明显优于西药组、中药组,差异有统计学意义(P<0.05)。治疗期间,中药联合贴敷组不良反应发生率8.33%(4/48)与西药组6.25%(3/48)、中药组4.17%(2/48)比较,差异无统计学意义(P>0.05)。治疗6个月后中药联合贴敷组疾病复发率4.17%(2/48)低于西药组18.75%(9/48)、中药组16.67(8/48),差异有统计学意义(P<0.05)。结论联合采取咳喘定穴位贴敷及小柴胡汤合半夏厚朴汤治疗痰浊阻肺证COPD效果显著,可有效缓解患者临床症状,改善肺功能及机体运动耐力,利于提升疾病整体干预效果,降低疾病复发率,且具有安全性。